Osteoarthritis - Pipeline Insight, 2024

This Osteoarthritis - Pipeline Insight, 2024,” report provides comprehensive insights about 130+ companies and 130+ pipeline drugs in Osteoarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Osteoarthritis Understanding

Osteoarthritis: Overview

Osteoarthritis (OA) is the most common form of arthritis. Some people call it degenerative joint disease or “wear and tear” arthritis. It occurs most frequently in the hands, hips, and knees. Osteoarthritis is most likely to affect the joints that bear most of weight, such as the knees and feet. Joints that the person use a lot in everyday life, such as the joints of the hand, are also commonly affected.

The main symptoms of osteoarthritis are pain and sometimes stiffness in the affected joints. The pain tends to be worse when the person move the joint or at the end of the day. Osteoarthritis is a leading cause of disability and source of societal cost in older adults. With an ageing and increasingly obese population, this syndrome is becoming even more prevalent than in previous decades.

Osteoarthritis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Osteoarthritis pipeline landscape is provided which includes the disease overview and Osteoarthritis treatment guidelines. The assessment part of the report embraces, in depth Osteoarthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Osteoarthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence R&D Osteoarthritis. The therapies under development are focused on novel approaches to treat/improve Osteoarthritis.

• In January 2021 Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, and Glyco Mimetics announced APL-106 (uproleselan) has been granted Breakthrough Therapy Designation (BTD) from the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) for the treatment of relapsed/refractory acute myeloid leukemia(AML).
• In January 2022, Astex Pharmaceuticals, Inc. announced that the European Commission (EC) has granted orphan-drug designation (ODD) to the oral fixed dose combination of decitabine and cedazuridine (ASTX727) for the treatment of Acute Myeloid Leukemia (AML).

Osteoarthritis Emerging Drugs

Lorecivivint: Biosplice Therapeutics
Lorecivivint (SM04690) is a small-molecule CLK/DYRK1A inhibitor that modulates Wnt and inflammatory pathways and is in development as a potential disease-modifying osteoarthritis drug. Vehicle-controlled preclinical data suggest that lorecivivint has a dual mechanism of action with three potential effects on joint health: reduction of inflammation, slowing of cartilage breakdown, and generation of cartilage. The drug is currently in Phase III stage of clinical trial evaluation to treat the patients suffering from osteoarthritis
CYP 004: Cynata Therapeutics
Cynata’s CYP-004 MSC product is the subject of a Phase III clinical trial being sponsored by the University of Sydney and funded by an Australian Government National Health and Medical Research Council (NHMRC) competitive Project Grant in addition to in-kind contributions from participating institutions. Cynata will supply Cymerus MSCs for use in the trial and will not be required to contribute any cash to fund the project. The clinical trial commenced in late 2020 and is entitled Stem Cells as a symptom- and str Ucture-modifying Treatment for medial tibiofemoral OsteoaRthritis (SCUlp TOR): a randomisedplacebo-controlledtrial
JTA-004: Bone Therapeutics
JTA-004 is Bone Therapeutics’ next generation of intra-articular injectable, which is currently in phase III development for the treatment of osteoarthritic pain in the knee. Consisting of a unique patented mix of plasma proteins, hyaluronic acid - a natural component of knee synovial fluid, and a fast-acting analgesic, JTA-004 intends to provide added lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic pain. In a phase II study involving 164 patients, JTA-004 showed an improved pain relief at 3 and 6 months compared to Hylan G-F 20, the global market leader in osteoarthritis treatment.

SMUP-IA-01: Medipost
SMUP-IA-01, SMUP allogeneic umbilical cord blood-derived mesenchymal stem cells, is currently under development for the treatment and prevention of Osteoarthritis. In SMUP-IA-01’s phase I clinical trials in Korea, 12 patients with knee osteoarthritis were given a single injection into their knee joint cavity at Seoul National University Hospital. The response to the drug was then evaluated for 6 months, and the results were shown to demonstrate the safety and improvement of joint function and pain.

TTAX03: Tissue Tech
TTAX03 is a sterile, lyophilized and micronized particulate human Amniotic and umbilical cord co product manufactured using aseptic processing followed by terminal sterilization by gamma irradiation in compliance with current Good Tissue Practices (c GTP) and current Good Manufacturing Practices (c GMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells. TTAX03 is currently being investigated in Phase II stage of development for the treatment of patients withkneeosteoarthritis

Osteoarthritis: Therapeutic Assessment

This segment of the report provides insights about the Osteoarthritis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Osteoarthritis

There are approx. 130+ key companies which are developing the therapies Osteoarthritis. The companies which have their Osteoarthritis drug candidates in the most advanced stage, i.e phase III include Biosplice Therapeutics

Phases

This report covers around 130+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Osteoarthritis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Osteoarthritis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Osteoarthritis drugs.

Osteoarthritis Report Insights

• Osteoarthritis Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Osteoarthritis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Osteoarthritis drugs?
• How many Osteoarthritis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Osteoarthritis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Osteoarthritis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Osteoarthritis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Biosplice Therapeutics
• Gilead Sciences
• Flexion Therapeutics
• GlaxoSmithKline
• Levicept
• Arthrogen
• Personalized Stem Cells
• Peptinov
• Asahi Kasei Pharma
• Taiwan Bio Therapeutics
• Oli PassCorporation
• Bioventus
• Medipost
• Moebius Medical
• ReqMed
• TissueTech
• Novartis
• AstraZeneca
• Biosplice Therapeutics
• Cynata Therapeutics
• Bone Therapeutics S.A
• Regeneron Pharmaceuticals
• Techfields Pharma
• Ampio Pharmaceuticals
• Taiwan Liposomal Company
• K-STEMCELL
• Stempeutics
• Levolta Pharmaceuticals

Key Products

• GLPG-0555
• FX201
• GSK 3858279
• LEVI 04
• ART-I02
• PSC-01
• PPV 06
• AK1830
• Chondrochymal
• OLP-1002
• PTP-001
• SMUP-IA-01
• MM-II
• Pentosan polysulfate
• TTAX03
• LRX712
• MEDI7352
• Lorecivivint
• CYP 004
• JTA-004
• Fasinumab
• X0002
• Ampion
• TLC599
• JOINTSTEM
• Stempeucel
• VOLT01

This product will be delivered within 1-3 business days.